Physician profile
Dmitriy Elkin
NPI 1760431761
$10,423.14
in general payments reported to CMS, 2019-2025
49 companies · $17.54 in 2025
The $17.54 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,971 · 2020: $1,820 · 2021: $2,703 · 2022: $1,851 · 2023: $1,061 · 2025: $17.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,483.37 | 2019-2023 | |
| Amgen INC. | $1,460.30 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $1,033.62 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $710.03 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $641.64 | 2019-2023 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $542.64 | 2019-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $478.63 | 2019-2022 | |
| Pfizer INC. | $415.25 | 2019-2023 | |
| Allergan, INC. | $367.05 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.22 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $305.79 | 2019-2022 | |
| Redhill Biopharma INC. | $297.52 | 2020-2022 | |
| Glaxosmithkline, LLC. | $288.97 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $250.48 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $195.34 | 2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Elkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.